Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Denali Therapeutics Inc. (DNLI:NASDAQ), powered by AI.
Denali Therapeutics Inc. is currently trading at $23.94. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Denali Therapeutics Inc. on Alpha Lenz.
Denali Therapeutics Inc.'s P/E ratio is -8.0.
“Denali Therapeutics Inc. trades at a P/E of -8.0 (undervalued) with modest ROE of -45.7%.”
Ask for details →Denali Therapeutics Inc. is a biotechnology company focused on discovering and developing therapeutic interventions for neurodegenerative diseases. The primary aim of the company is to combat disorders linked to degeneration of the nervous system, such as Alzheimer's, Parkinson's, and ALS, by targeting and addressing underlying mechanisms of these diseases. Denali Therapeutics employs a unique engineering-driven approach, leveraging its deep understanding of biological pathways to create therapies that can cross the blood-brain barrier, an essential obstacle in the treatment of central nervous system diseases. Based in South San Francisco, California, Denali Therapeutics is at the forefront of the biotech industry, collaborating with research institutions and other pharmaceutical companies to advance its pipeline of potential treatments. Its work is pivotal in addressing unmet medical needs related to neurodegeneration, positioning the company as an important player in the pursuit of innovative healthcare solutions aimed at improving the quality of life for affected patients.
“Denali Therapeutics Inc. trades at a P/E of -8.0 (undervalued) with modest ROE of -45.7%.”
Ask for details →Denali Therapeutics Inc. (ticker: DNLI) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 486 employees. Market cap is $4.1B.
The current price is $23.94 with a P/E ratio of -8.03x and P/B of 4.06x.
ROE is -45.69%.